Articles related to GLP-1 RECEPTOR AGONISTS

Semaglutide use before or during pregnancy was associated with greater gestational weight gain and several adverse outcomes in a retrospective cohort, although similar findings among former users complicate attribution to direct fetal exposure.

Semaglutide use was associated with lower psychiatric hospitalization and bipolar-relapse hospitalization risks among Swedish adults with bipolar disorder receiving antidiabetic medication, although the observational findings did not establish a therapeutic effect.

An editorial in Obesity highlights emerging evidence that GLP-1 receptor agonists may provide benefits beyond weight loss and glycemic control, while emphasizing unresolved questions regarding muscle preservation, nutritional status, and potential effects on substance use disorders.

The FDA approved tirzepatide to reduce major cardiovascular event risk in high-risk adults with type 2 diabetes. SURPASS-CVOT established noninferiority to dulaglutide rather than cardiovascular superiority.

A primary care physician describes combining nutrition counseling, individualized monitoring, and pharmacotherapy in obesity care. The interview offers a practice philosophy rather than comparative evidence supporting one treatment strategy.

Emerging reports suggest some patients experience emotional blunting or reduced reward responsiveness after starting GLP-1 receptor agonists. Current evidence remains mixed, and available data have not established a causal relationship between GLP-1 therapy and diminished antidepressant response.